LEXARIA BIOSCIENCE CORP. (LEXX) Gross Margin
- Gross margin · 12 months: Value 100.00%; Formula and calculation Gross profit / revenue. Period ending 2026-05-31..
Gross margin
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 100.00% | Gross profit / revenue. Period ending 2026-05-31. $194.00K ÷ $194.00K × 100 ≈ 100.00% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 194.00K USD | Gross Profit |
| Revenue | 194.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 0.00 USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-05-31 | $194.00K | $194.00K | $0.00 | 100.00% |
| 2026-02-28 | $368.00K | $368.00K | $0.00 | 100.00% |
| 2025-11-30 | $522.00K | $522.00K | $0.00 | 100.00% |
| 2025-08-31 | $703.20K | $705.92K | $2.72K | 99.61% |
| 2025-05-31 | $613.20K | $615.92K | $2.72K | 99.56% |
| 2025-02-28 | $523.20K | $525.92K | $2.72K | 99.48% |
| 2024-11-30 | $494.20K | $496.92K | $2.72K | 99.45% |
| 2024-08-31 | $459.46K | $464.28K | $4.82K | 98.96% |
| 2024-05-31 | $406.20K | $411.02K | $4.82K | 98.83% |
| 2024-02-29 | $387.16K | $404.73K | $17.57K | 95.66% |
| 2023-11-30 | $259.22K | $279.75K | $20.53K | 92.66% |
| 2023-08-31 | $194.71K | $226.21K | $31.50K | 86.07% |
| 2023-05-31 | $268.04K | $340.79K | $72.75K | 78.65% |
| 2023-05-11 | (m) | (m) | (m) | (m) |
| 2023-02-28 | $268.72K | $347.36K | $78.64K | 77.36% |
| 2022-11-30 | $260.93K | $342.99K | $82.07K | 76.07% |
| 2022-08-31 | $183.56K | $255.40K | $71.84K | 71.87% |
| 2022-05-31 | $124.37K | $175.27K | $50.90K | 70.96% |
| 2022-02-28 | $187.35K | $279.61K | $92.25K | 67.01% |
| 2021-11-30 | $324.52K | $440.96K | $116.44K | 73.59% |
| 2021-08-31 | $547.39K | $722.74K | $175.35K | 75.74% |
| 2021-05-31 | $657.32K | $825.46K | $168.14K | 79.63% |
| 2021-02-28 | $644.11K | $772.57K | $128.47K | 83.37% |
| 2020-11-30 | $513.86K | $669.87K | $156.00K | 76.71% |
| 2020-08-31 | $285.17K | $384.54K | $99.38K | 74.16% |
| 2020-05-31 | $274.70K | $375.93K | $101.23K | 73.07% |
| 2020-02-29 | $270.43K | $354.43K | $84.00K | 76.30% |
| 2019-11-30 | $233.90K | $262.48K | $28.59K | 89.11% |
| 2019-08-31 | $199.72K | $222.61K | $22.89K | 89.72% |
| 2019-05-31 | $182.95K | (m) | $10.89K | (m) |
| 2019-02-28 | $264.03K | (m) | $10.22K | (m) |
| 2018-11-30 | $409.62K | (m) | $21.24K | (m) |
| 2018-08-31 | $408.10K | (m) | $25.18K | (m) |
| 2018-05-31 | $322.45K | (m) | (m) | (m) |
| 2018-02-28 | $204.60K | (m) | (m) | (m) |
| 2017-11-30 | $44.09K | (m) | (m) | (m) |
| 2017-08-31 | $33.89K | (m) | (m) | (m) |
| 2017-05-31 | $32.01K | (m) | (m) | (m) |
| 2017-02-28 | (m) | (m) | (m) | (m) |
| 2016-11-30 | $7.04K | (m) | (m) | (m) |
| 2016-08-31 | $-4.90K | (m) | (m) | (m) |
| 2016-05-31 | $-24.28K | (m) | (m) | (m) |
| 2016-02-29 | $-23.69K | (m) | (m) | (m) |
| 2015-11-30 | $-18.78K | (m) | (m) | (m) |
| 2015-08-31 | $-15.18K | (m) | (m) | (m) |
| 2015-05-31 | (m) | (m) | (m) | (m) |
| 2015-02-28 | (m) | (m) | (m) | (m) |
| 2014-11-30 | (m) | (m) | (m) | (m) |
| 2014-08-31 | (m) | (m) | (m) | (m) |
| 2014-07-31 | $154.17K | (m) | (m) | (m) |
| 2014-05-31 | (m) | (m) | (m) | (m) |
| 2014-04-30 | $176.56K | (m) | (m) | (m) |
| 2014-02-28 | (m) | (m) | (m) | (m) |
| 2014-01-31 | $207.31K | (m) | (m) | (m) |
| 2013-10-31 | $302.25K | (m) | (m) | (m) |
| 2013-08-31 | (m) | (m) | (m) | (m) |
| 2013-07-31 | $496.23K | (m) | (m) | (m) |
| 2013-04-30 | $685.21K | (m) | (m) | (m) |
| 2013-01-31 | $598.64K | (m) | (m) | (m) |
| 2012-10-31 | $574.49K | (m) | (m) | (m) |
| 2012-07-31 | $535.74K | (m) | (m) | (m) |
| 2012-04-30 | $444.96K | (m) | (m) | (m) |
| 2012-01-31 | $519.06K | (m) | (m) | (m) |
| 2011-10-31 | $465.91K | (m) | (m) | (m) |
| 2011-07-31 | (m) | (m) | (m) | (m) |
| 2011-04-30 | (m) | (m) | (m) | (m) |
| 2011-01-31 | (m) | (m) | (m) | (m) |
| 2010-10-31 | $88.86K | (m) | (m) | (m) |
| 2010-07-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |